Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
The Canyon Creek Village neighborhood in San Antonio, Texas deserves accurate, unexaggerated information about GLP-1 therapy — not the marketing version, but the actual peer-reviewed clinical data and a physician who honestly evaluates your health profile before prescribing. RealityPeptides shows every Canyon Creek Village patient the exact trial numbers up front: semaglutide 14.9% over 68 weeks (STEP 1, NEJM 2021), tirzepatide up to 22.5% over 72 weeks (SURMOUNT-1, NEJM 2022). These are what the controlled trials documented — not what the best-case testimonial claimed.
For Canyon Creek Village patients, the documented timeline is straightforward: initial measurable weight loss begins at weeks 4–8 after reaching maintenance dose. Maximum outcomes are reached at 12 to 18 months of consistent therapy. Your FDA-approved medication ships from a PCAB-accredited pharmacy to any Canyon Creek Village address within 2–5 business days. Regular telehealth check-ins track your progress against the trial benchmarks — transparently, not optimistically.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
Landmark randomized controlled trials in the New England Journal of Medicine establish the efficacy profile of FDA-approved GLP-1 medications available to Canyon Creek Village, San Antonio residents:
Telehealth prescribing of GLP-1 receptor agonists in Texas is conducted by board-certified, -licensed physicians through HIPAA-compliant platforms. GLP-1 medications are not DEA-scheduled controlled substances and may be prescribed via telehealth after a valid clinical evaluation.
1,961 adults with obesity or overweight randomized to semaglutide 2.4 mg weekly vs. placebo. At 68 weeks, the semaglutide group achieved a mean 14.9% body weight reduction, compared to 2.4% in the placebo group. 86.4% of semaglutide patients lost at least 5% of body weight. 69.1% lost at least 10%. 50.5% lost at least 15%. These are the documented facts for Canyon Creek Village patients considering semaglutide.
2,539 adults with obesity randomized to tirzepatide (5, 10, or 15 mg weekly) vs. placebo over 72 weeks. Mean weight reductions by dose: 5 mg = 15%, 10 mg = 19.5%, 15 mg = 20.9%. The highest-dose group's mean was 22.5%. 91% of 15 mg patients lost at least 5% of body weight. Currently the highest-documented efficacy of any FDA-approved GLP-1 agent — a fact Canyon Creek Village patients can use to make an informed choice.
Trial averages are population means — they are not guarantees or individual predictions. Roughly half of trial participants in Canyon Creek Village-equivalent conditions did better than the average; half did less. Your board-certified physician at RealityPeptides will review your actual BMI, metabolic history, and health data to give you a personalized projection anchored in the trial evidence, not in the headline number that the industry uses as a marketing tool.
The documented trial figures for Canyon Creek Village patients: semaglutide produced a 14.9% average body weight reduction over 68 weeks (STEP 1, NEJM 2021, n=1,961). Tirzepatide produced up to 22.5% in the highest-dose group over 72 weeks (SURMOUNT-1, NEJM 2022, n=2,539). Liraglutide produced approximately 8% over 56 weeks (SCALE trial). These are population averages from peer-reviewed trials — your board-certified physician will give you an honest, personalized projection for your specific starting profile in Canyon Creek Village, not the best-case number from the brochure.
Initial measurable weight loss for Canyon Creek Village patients typically occurs within 4–8 weeks after reaching the effective maintenance dose. The full trial-documented outcomes — the 14–22% benchmarks — are reached at 12 to 18 months. Many patients in Canyon Creek Village experience a normal plateau around months 4–6 that can be discouraging; your physician will walk you through the documented progression curve at intake so you know what to expect and stay on course throughout the full protocol.
Complete our online health intake with your real medical history, current medications, and weight goals. A board-certified physician will review your actual health data — not an algorithm — and give you a frank, evidence-based assessment of which GLP-1 medication fits your profile and what documented outcomes the trials support for your starting point. If approved, your FDA-approved medication ships to any Canyon Creek Village address within 2–5 business days from a PCAB-accredited pharmacy. No inflated promises, no surprises — just the data and a plan built on it.
Local weight loss and GLP-1 providers serving the Canyon Creek Village, San Antonio area, based on Google Business listings.
15909 San Pedro Ave Ste 204, San Antonio, TX 78232
4.9/5 ★ (0 reviews)
11103 San Pedro Ave STE 170
5/5 ★ (51 reviews)
2034 Babcock Rd, San Antonio, TX 78229
4.8/5 ★ (198 reviews)
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
